The DEA banned a drug some opioid users called a miracle

Summary

The Drug Enforcement Administration placed experimental compound SR-17018 on Schedule I, halting planned human clinical trials and cutting off illicit access for opioid users. Researchers and reform advocates warn the ban disrupts critical addiction research, while regulators argue the substance poses trafficking and abuse risks.

Key Takeaways

1. Funded by the National Institute on Drug Abuse, in 2017 she and other scientists revealed in the science journal Cell that several compounds—including a particularly promising one called SR-17018—could relieve pain in mice without causing respiratory depression.
2. But all of that came crashing to a halt when the US Drug Enforcement Administration emergency-scheduled SR-17018 as a Schedule I controlled substance in late August, putting it in the same category as heroin with ‘no currently accepted medical use and a high potential for abuse.’
3. The emergency scheduling will last two years, with a potential one-year extension—but the DEA could also permanently schedule the drug in that time period, a process that requires public and scientific input.

Statement Breakdown

• Claimed Facts: 65% of statements the article presents as facts
• Opinions: 35% of statements classified as editorial or subjective
• Claims: 0% of statements surfaced for additional reader evaluation

Credibility & Bias Reasoning

Credibility assessment: The reporting relies on on-the-record scientific researchers, named legal advocates, user testimonials, and official DEA public filings. While user experiences are inherently anecdotal and human clinical trial data remains absent, the article contextualizes animal study findings clearly and presents the regulatory stance directly from agency documents.

Bias assessment: Harm-Reduction Sympathetic. The narrative gives sympathetic coverage to individuals using experimental synthetic compounds for addiction recovery and foregrounds researcher frustration over federal scheduling. The Drug Enforcement Administration perspective is represented primarily through excerpted official regulatory filings rather than direct responsive interviews.

Note: Relies on pre-clinical animal studies, personal user anecdotes, and official DEA filings.

Credibility flag: Agency & User Reports

Claimed Facts (3)

• Describes specific experimental outcomes achieved in laboratory animal models.
• Reports the formal legal petition filed to intervene against the regulatory classification.
• Details official government forensic data used as evidentiary grounds for the emergency action.

Key Sources

• Laura Bohn — Senior associate vice president of research at University of South Florida Health
• US Drug Enforcement Administration — Federal law enforcement agency regulating controlled substances
• Robert Rush — Executive director of Rights and Reason Project and legal counsel to Laura Bohn
• Jim Bates — Individual opioid user and kitchen manager based in Oklahoma
• Michael — Individual former user of 7-OH